
## Rowan E Miller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3544715/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. Journal of Gynecologic Oncology, 2022, 33, .	2.2	18
2	Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 271, 138-144.	1.1	6
3	PARP inhibitors and immunotherapy in ovarian and endometrial cancers. British Journal of Radiology, 2021, 94, 20210002.	2.2	4
4	Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy. Cancer Journal (Sudbury, Mass ), 2021, 27, 506-510.	2.0	1
5	Targeted therapies in gynaecological cancers. Histopathology, 2020, 76, 157-170.	2.9	30
6	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. Current Opinion in Oncology, 2020, 32, 442-450.	2.4	10
7	Targeting HPV in gynaecological cancers – Current status, ongoing challenges and future directions. Women's Health, 2020, 16, 174550652096170.	1.5	3
8	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers. Cancer Discovery, 2020, 10, 1528-1543.	9.4	82
9	COVID-19, the Future Vaccine and What It Means for Cancer Patients on Immunotherapy. Frontiers in Oncology, 2020, 10, 631611.	2.8	2
10	Olaparib maintenance for first-line treatment of ovarian cancer:Âwill SOLO1 reset the standard of care?. Future Oncology, 2019, 15, 1845-1853.	2.4	12
11	Body Mass Index and Outcomes in Germ-Cell Tumors. Clinical Genitourinary Cancer, 2019, 17, 283-290.	1.9	2
12	Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. European Urology Focus, 2017, 3, 621-628.	3.1	10
13	The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers. Gynecologic Oncology, 2017, 144, 8-10.	1.4	0
14	Outcome of patients with advanced endometrial and cervical cancer treated in a phase 1 unit Journal of Clinical Oncology, 2017, 35, 5597-5597.	1.6	0
15	Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e259-e268.	3.8	14
16	Diagnosis and management of penile cancer. Trends in Urology & Men's Health, 2016, 7, 17-20.	0.4	2
17	The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. Clinical Advances in Hematology and Oncology, 2016, 14, 619-27.	0.3	8
18	The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations. Clinical Advances in Hematology and Oncology, 2016, 14, 704-11.	0.3	5